10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares of UK-based Avacta Group soared nearly 58% to 45.00 pence this morning, after it revealed a major co-development partnership with a US business. 24 July 2018
In its attempts to show the effectiveness of using two drug combinations in HIV, ViiV Healthcare has added more data to its evidence base. 24 July 2018
Shares in East Coast, USA-based Biogen were up 6% just ahead of the opening bell in New York, after the firm released positive second quarter results on Tuesday. 24 July 2018
China’s BeiGene says that its investigational BTK inhibitor zanubrutinib has been granted Fast Track designation by the US Food and Drug Administration for the treatment of patients with Waldenström macroglobulinemia (WM). 24 July 2018
A new GlobalData report suggests that China, already the second-largest market in the acute ischemic stroke (AIS) market, is set to grow even further due to the aging population, giving stem cell therapies a chance to penetrate in the region. 24 July 2018
Changsheng Biotechnology is the subject of an ongoing controversy this week, after an inspection in mid-July found the company had fabricated production and inspection documents related to the production of 250,000 faulty rabies vaccines. 23 July 2018
US pharma major Eli Lilly has entered into a multi-million dollar agreement for the discovery and development of translation inhibitors for several target proteins. 22 July 2018
Swedish Orphan Biovitrium (Sobi) announced on Friday that it had reached an exclusive licensing deal with Novimmune for rights to emapalumab. 20 July 2018
Roche has entered into a multiyear collaboration with PureTech Health to advance the latter’s milk-derived exosome platform technology for the oral administration of the Swiss pharma giant’s antisense oligonucleotide platform. 20 July 2018
Kite, a Gilead Sciences subsidiary, and privately-held Dutch firm Gadeta have entered into a strategic collaboration to develop novel gamma delta T cell receptor (TCR) therapies in various cancers. 20 July 2018
It’s been a rapid journey for the biopharma industry over the last few years. We’ve seen the industry stagger to its feet – surpassing notable early setbacks caused by lack of control over hyperallergenic drugs. 20 July 2018
Bristol-Myers Squibb has entered into a clinical trial collaboration immuno-oncology firm Gritstone Oncology to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001. 19 July 2018
Swiss pharma giant Novartishas entered into an exclusive license agreement with two biotech companies – Belgo-Dutch Galapagos and Germany’s MorphoSys - regarding their atopic dermatitis compound MOR106. 19 July 2018
Swiss pharma giant Roche has been awarded a Breakthrough Therapy badge for a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) against hepatocellular carcinoma (HCC) in the first-line setting. 19 July 2018
The US Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. 19 July 2018
A 16-week Phase III study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. 19 July 2018
The Australian government will provide A$50 million (S37 million) to support some of Australia’s sickest patients, battling the most aggressive and deadliest cancers, to access potentially life-saving medical treatment, Health Minister Greg Hunt revealed today. 18 July 2018
Boehringer Ingelheim has elected to exercise an option with US biotech Eureka Therapeutics for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients. 18 July 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024